Intellia Therapeutics (NTLA) Net Margin (2016 - 2025)
Historic Net Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 760.14%.
- Intellia Therapeutics' Net Margin rose 6957700.0% to 760.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 774.19%, marking a year-over-year increase of 3586000.0%. This contributed to the annual value of 840.5% for FY2024, which is 4426400.0% up from last year.
- Per Intellia Therapeutics' latest filing, its Net Margin stood at 760.14% for Q3 2025, which was up 6957700.0% from 720.21% recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Net Margin ranged from a high of 6647.52% in Q4 2023 and a low of 23881.33% during Q3 2021
- Over the past 5 years, Intellia Therapeutics' median Net Margin value was 780.83% (recorded in 2022), while the average stood at 1714.08%.
- In the last 5 years, Intellia Therapeutics' Net Margin tumbled by -237560400bps in 2021 and then skyrocketed by 231005000bps in 2022.
- Over the past 5 years, Intellia Therapeutics' Net Margin (Quarter) stood at 621.69% in 2021, then fell by -24bps to 771.63% in 2022, then surged by 961bps to 6647.52% in 2023, then crashed by -115bps to 977.29% in 2024, then increased by 22bps to 760.14% in 2025.
- Its Net Margin was 760.14% in Q3 2025, compared to 720.21% in Q2 2025 and 674.83% in Q1 2025.